FirstHealth of the Carolinas

Clinical Trial Details

Study Title: SWOG 1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer
Study Type: Interventional
Study Condition: Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
Investigator: Dr. Charles Kuzma
Phone: (910) 715-3500
Research Coordinator: Lori DeSpain
Phone: (910) 715-2200
Eligibility Criteria: Men and women ages 18 and older, diagnosed with advanced or metastatic cancer of the esophagus, stomach, or gastroesophageal junction (GEJ). For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Southwest Oncology Group
Study Rationale: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating tumor cells.
Study Purpose: This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer.
Study Link: http://clinicaltrials.gov/ct2/show/NCT01498289
   
 
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @ LinkedIn.com
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.